Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

@article{Spaepen2002EarlyRP,
  title={Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.},
  author={Karoline Spaepen and Sigrid S Stroobants and Pierre Dupont and Peter Vandenberghe and J. -P. Thomas and Tjibbe de Groot and Jan Balzarini and Christiane de Wolf-Peeters and Luc Mortelmans and Gregor E. G. Verhoef},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2002},
  volume={13 9},
  pages={1356-63}
}
BACKGROUND Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS